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Introduction. Nonalcoholicfattyliver disease(NAFLD) is animportantcause ofliver diseaseinadults andthe mostcommoncause
of liver disease in children (Lavine and Schwimmer 2004). The abnormalities include increased liver fat without inﬂammation
(steatosis) and nonalcoholic steatohepatitis (NASH). NASH may lead to ﬁbrosis, cirrhosis, and ultimately liver failure if it is not
treated(Matteonietal.1999).Theobjectiveofthestudyistoestimatethemagnitudeoftheproblemwhichwillhelpustoformulate
strategies in managingthe potentially diﬃcult problem. Materials and Methods. We included 1000 individuals between the ages of
30and 50 years who came forannual checkup. The patients withother comorbidities like diabetes, ischemic heart disease, chronic
liverdisease,orrenaldiseaseswere excluded fromthestudy. Historyofalcoholingestionwasalsotaken;anyindividualwithhistory
of alcoholintakewasalsoexcluded. All of them underwent investigationsincluding CBC, LFTs, height andweight. The individuals
whowerefoundtohaveincreasedALT(50to150u/L)furtherunderwentinvestigationsincludingultrasoundofabdomenhepatitis
b and c serology RA and ANA antibodies. All the individuals who were found to have viral or autoimmune illness were excluded
from the study. The individuals having raised ALT levels and ultrasound evidence of fatty liver were taken. Results. 13.5% of the
individuals were found to have NAFLD among those selected for the study. Conclusion. Mass campaign regarding physical and
dietary measures needs to be undertaken in general masses regarding the gravity and potential prevention of the disease.
1.Introduction
Nonalcoholic fatty liver disease (NAFLD) is a clinical spec-
trum of liver abnormalities associated with obesity, a com-
mon liver disease, and also the most common cause of liver
disease in children [1]. The abnormalities include steatosis
(increased liver fat without inﬂammation) and nonalcohol-
ic steatohepatitis (NASH, increased liver fat with inﬂamma-
tion). NASH may lead to ﬁbrosis, cirrhosis, and ultimately
liver failure if it is not treated [2].
The pathogenesis of NAFLD in overweight and obese
individuals is not exactly known. It appears to be related to
insulin resistance. There are important clinical associations
between NAFLD and elements of the metabolic syndrome,
including insulin resistance, dyslipidemia, and hypertension,
independent of the degree of obesity. Therefore, individuals
with NAFLD should be carefully evaluated for each of
these comorbidities and have counseling at national level
about nutrition, physical activity, and tobacco use to help
prevention of the development of cardiovascular disease and
type 2 diabetes mellitus along with chronic liver disease.
With the increased prevalence of childhood obesity, NAFLD
is increasingly seen in children also. It is more common in
males [3, 4]. NASH may progress to cirrhosis in up to 20
percent of patients [2, 5]. NASH is now recognized to be a
leading cause of cryptogenic cirrhosis [5].
The prevalence depends upon the population (i.e., refer-
ral community, ethnic group) and the deﬁnition (e.g., height
of aminotransferase elevation and/or ultrasonographic ﬁnd-
ings). Imaging may conﬁrm the presence of fatty liver,
indicated by increased echogenicity. However, the severity
of liver involvement does not correlate with radiographic
features, clinical features, or the degree of elevation of liver
transaminases.
Asian population as a race is a risk factor for diabetes
mellitus and obesity because increase in incidence of NASH
in this ethnic group. This study was designed to ﬁnd out the
prevalence of NAFLD in our healthy population, and this
will further lead us in formulating mass campaign regarding
physical and dietary measures that need to be under taken
in generalmasses regarding the gravity and potential preven-
tion of the disease.2 ISRN Gastroenterology
Table 1: Some important clinicalfeatures.
No. of individuals (n = 135)
NAFLD 129
Hepatitis B&C 06
Fatty change on usg 86
BMI (Mean) 27.1
ALT bet 50–100u/L 113
ALT bet 100–150u/L 16
Mean Age yrs 39.2
2.Materialsand Methods
The study was conducted at PNS Shifa Hospital, Karachi
which is a tertiary care hospital. We included 1000 consec-
utive individuals between the ages of 30 and 50 years who
came for medical checkup in the last three months of 2010.
The patients with other comorbidities like diabetes, ischemic
heart disease, chronic liver disease and renal diseases were
excluded from the study. History of alcohol ingestion was
also taken; any individual with history of alcohol intake was
also excluded.After fulﬁlling the inclusion and exclusion cri-
teria,952subjectswere selected. Theyundergoinvestigations
including CBC, LFTs, height, and weight. The individuals
who were foundto haveincreased ALT(50to 150uL)further
underwent investigations including ultrasound of abdomen
hepatitis b and c serology RA and ANA antibodies. The
individuals who were found to have viral or autoimmune
illness were again excluded from the study. The individuals
having raised ALT levels were taken as positive results. They
then subjected to ultrasound of abdomen to ﬁnd out the
radiological evidence of fatty change. Liver biopsy was not
done as most of the patients declined liver biopsy.
3.Results
A total of 952 patients were selected after fulﬁlling inclusion
and exclusion criteria. 135 patients had increased ALT levels.
Six patients found to have either HBV or HCV serology
positive. So a total of 129 patients had NAFLD (Figure 1).
113 patients have ALT between 50 and 100U/L and 16 had
ALT between 100 and 150U/L. The average BMI of selected
population for the study was 24.4, while average BMI was
27.1 in patients with increased ALT (Table 1). 86 patients
having raised ALT also had fatty change on ultrasound
examination (Figure 2).
4.Discussion
Nonalcoholic fatty liver disease is a spectrum of disorders
that range from simple hepatic steatosis without signiﬁcant
inﬂammation or ﬁbrosis to nonalcoholic steatohepatitis
with varying degrees of inﬂammation and ﬁbrosis. It is
an clinical entity with histological features that resemble
alcohol-induced liver injury, but by deﬁnition occurs in
patients with no history of alcohol intake. The histological
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Figure 2: Ultrasound changes of NAFLD.
without concomitant inﬂammation or ﬁbrosis to hepatic
steatosis associated with an inﬂammatory component that
may be associated with ﬁbrosis referred to as nonalcoholic
steatohepatitis (NASH). This may progress to cirrhosis in
up to 20 percent of patients. NASH is now recognized to
be a leading cause of cryptogenic cirrhosis. Although the
etiologyofNASHisunknown,itisfrequentlyassociatedwith
obesity, type 2 diabetes mellitus, and hyperlipidemia. The
combination of abdominal obesity, hypertension, diabetes,
and dyslipidemia has been called the metabolic syndrome
[6, 7].
The pathogenesis of nonalcoholic fatty liver disease has
not been fully elucidated. The most widely supported theory
implicates insulin resistance [8] as the key mechanism lead-
ing to hepatic steatosis, and perhaps also to steatohepatitis.
Another mechanism may be due to additional oxidative
injury and is required to manifest the necroinﬂammatory
component of steatohepatitis. Hepatic iron [9], leptin [10],
antioxidant deﬁciencies [11, 12], and intestinal bacteria
have all been suggested as potential oxidative stressors. The
patientslackahistory ofsigniﬁcant alcoholconsumptionbut
have liver biopsy ﬁndings indistinguishable from alcoholic
steatohepatitis.ISRN Gastroenterology 3
NASH is considered to be a subset of nonalcoholic fatty
liver disease. The prevalence of NASHin the general popula-
tion is yet incompletely understood. The prevalence of non-
alcoholic fatty liver disease (NAFLD) is better understood
which can be detected noninvasively. The major risk factors
for NAFLD are central obesity, type 2 diabetes mellitus,
dyslipidemia, and metabolic syndrome. NAFLD is the most
common liver disorder in western industrialized countries,
aﬀecting 20 to 40 percent of the general population [13].
Estimates ofcurrentprevalencerange from5 to30 percentin
theAsia-Paciﬁc region, depending onthepopulationstudied
[14, 15]. In our population, data is lacking. This study will
help us to help ﬁnding not only the data in adult population.
However, NAFLD is probably the most common cause of
liver disease in the preadolescent and adolescent age groups,
but the majority of cases occur between the ages of 40 and
60. NAFLD and NASH are more common in men. The male
predilection may reﬂect that men are more likely to fulﬁll
criteria for the metabolic syndrome which will also help us
ﬁnd the strategies for the management of such problems.
Most patients with NASH are asymptomatic although
fatigue, malaise, and vague right upper abdominal discom-
fort bring some patients to medical attention [1]. The most
common presentation is elevation of liver aminotransferases
detected on routine laboratory testing. Hepatomegaly is a
frequent ﬁnding. Serum AST and ALT are elevated in almost
90 percent of patients [1]. The AST/ALT ratio is usually
less than 1; this is much lower than the ratio in alcoholic
hepatitis, which is usually above 2 and averaged 2.85 in one
report and 2.6 in another [16, 17].
Various radiological methods can detect the presence
of fat in the liver, but no imaging modality is able to
diﬀerentiate between the histological subtypes of relatively
benign nonalcoholic hepatic steatosis or more aggressive
NASH [18]. Ultrasonography often reveals a hyperechoic
texture or a bright liver because of diﬀuse fatty inﬁltration
[19]. However, this is a nonspeciﬁc ﬁnding and should not
be used to make the diagnosis of NAFLD. Both CT, and
MRI can identify steatosis but are not suﬃciently sensitive
to detect inﬂammation or ﬁbrosis [20]. Magnetic resonance
spectroscopy has the advantage over the other commonly
usedimaging modalities ofultrasonography, CTand MRI,as
it is quantitative rather than qualitative or semiquantitative.
One of the diﬃculties in determining test characteristics of
the imaging tests for ruling in or ruling out NAFLD is that
not all patients undergo conﬁrmation by liver biopsy.
The indications for liver biopsy for suspected NAFLD
have not been established in either children or adults and
remain controversial. Liver biopsy is the only way to reliably
distinguish between simple steatosis steatohepatitis, and
ﬁbrosis, and can also be helpful in excluding other causes
of elevated serum aminotransferases. On the other hand,
because there is currently no speciﬁc treatment for NAFLD
other than weight management, the results of a liver biopsy
are not likely to provide clinical beneﬁt. Therefore, the
beneﬁts of performing a liver biopsy may not outweigh the
costs and risks, unless there are speciﬁc features that suggest
more severe or progressive liver disease.
Although the etiology of NASH is unknown, it is fre-
quently associated with obesity, type 2 diabetes mellitus,
and hyperlipidemia. The constellation of abdominal obesity,
hypertension, diabetes, and dyslipidemia has been called
the metabolic syndrome, syndrome X, the deadly quartet,
the insulin resistance syndrome, and the obesity dyslipi-
demia syndrome. One study used this deﬁnition to seek
the metabolic syndrome in 304 consecutive patients with
NAFLD of whom 120 (74 percent) were diagnosed with
NASH.Metabolicsyndrome was signiﬁcantly more common
in patients with NASH compared with those with fatty liver
alone (88 versus53percent). Obesity has beenreported in69
to 100 percent of cases. Type 2 diabetes, a frequent compli-
cation of obesity, has been described in 34 to 75 percent of
patients with NASH. Hyperlipidemia (hypertriglyceridemia
and/or hypercholesterolemia), which is frequently associated
with both obesity and type 2 diabetes, has been reported in
20 to 80 percent of patients with NASH.
There is no proven eﬀective therapy for NASH although
the modiﬁcation of risk factors, such as obesity, hyperlipi-
demia, and poordiabetic control,is generallyrecommended.
Weight loss is the only therapy with reasonable evidence
supporting beneﬁt. Weight management is the only estab-
lished treatment for NAFLD; small nonrandomized studies
in children have shown improvement in liver histology or
aminotransferase activityafterweightloss[21–23].Emphasis
on physical activity seems appropriate because of its utility
in improving insulin sensitivity, which appears to be an
important pathway for the development of NAFLD.
5.Recommendations
Nonalcoholic fatty liver disease is unexpectedly a common
clinical problem which otherwise comes in to light when an
individualundergoesinvestigationsforanymedicalcheckup.
It is commonly associated with other metabolic illnesses
like diabetes mellitus, obesity, hyperlipidemias, and so forth.
It can lead to ﬁbrosis cirrhosis and hepatocellular carci-
noma.
There is little or no role of drugs which can modify the
course of the disease. However, only the diet modiﬁcations
and exercise have a deﬁnitive role in the treatment of the
potentially dangerous condition.
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